◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Dishman Carbogen Amcis Limited (DCAL) Financial History

Name: Dishman Carbogen Amcis Limited (DCAL) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-20

Dishman Carbogen Amcis Limited (DCAL) operates in the Biotechnology industry and is headquartered in Ahmedabad, India with about 934 employees. Its market capitalization is roughly ₹27 billion. In the fiscal year ended 2026-03-31, DCAL reported ₹28.8B in revenue and ₹974M in net income.

Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments.

Interactive charts & full statements →

DCAL Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹28.8B	₹26.4B	₹25.4B	₹23.2B
Gross Profit	₹24.5B	₹21.2B	₹19.3B	₹17.8B
Operating Income (EBIT)	₹2.0B	₹1.5B	(₹413M)	₹1.1B
Net Income	₹974M	₹32M	(₹1.5B)	(₹298M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DCAL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹8.5B	₹7.2B	₹7.1B	₹7.2B	₹6.8B
Gross Profit	₹7.2B	₹5.8B	₹6.1B	₹5.7B	₹5.8B
Operating Income (EBIT)	₹742M	₹287M	₹593M	₹736M	₹682M
Net Income	₹217M	(₹130M)	₹234M	₹431M	₹46M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DCAL Free Cash Flow History

DCAL Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹119.2B	₹100.0B	₹95.8B	₹94.5B	—
Total Liabilities	₹52.5B	₹41.7B	₹39.5B	₹36.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DCAL viewer.

Other Companies in Biotechnology

3696 · InSilico Medicine Cayman TopCo — HK$35 billion
2696 · Shanghai Henlius Biotech, Inc. — HK$33 billion
BIIB · Biogen — $32 billion
2315 · Biocytogen Pharmaceuticals (Beijing) Co., Ltd. — HK$27 billion
9969 · InnoCare Pharma Limited — HK$26 billion
INCY · Incyte — $25 billion
4875 · MediciNova, Inc. — JPY 24 billion
PANACEABIO · Panacea Biotec Limited — ₹23 billion

← DC.A All “D” companies DCBBANK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.